Impact of External Radiotherapy on Survival after Stage I Endometrial Cancer: Results from a Population-Based Study

Pierre-Marie Tebeu1,4,5*, Helena M Verkooijen2, Youri Popowski3, Christine Bouchardy2, Frank Ludicke4, Massimo Usei2 and Attila L Major1,4

Keywords: Endometrial cancer; Radiotherapy; Survival

Introduction

Endometrial cancer is the most common genital tract malignancy in Western countries [1], and its incidence has increased considerably in recent decades [2]. More than 75% of endometrial cancers are still confined to the uterus at diagnosis (stage I) [3,4]. Among the most important predictors of local and distant recurrence for stage I tumours are the level of differentiation and the depth of the myometrial invasion [5].

Standard treatment for stage I endometrial cancer is hysterectomy with bilateral oophorectomy and pelvic lymphadenectomy [6]. Postoperative radiotherapy is often included in the treatment to prevent loco-regional relapse. Four randomised clinical trials evaluated the impact of post-operative radiotherapy on the outcome in early stage endometrial cancer [7-10]. The Gynaecologic Oncology Group randomised patients with stage IB (<50% myometrial invasion), stage IC (≥50% myometrial invasion) and occult stage II (microscopic invasion of the cervix) endometrial cancer to postoperative external radiotherapy or surgery alone. They confirmed the results of the Aalders' trial and the PORTEC trial [8,10] and many other single-centre observational studies by showing that external radiotherapy reduces the risk of loco-regional recurrence [8-15].

However, no study has shown a significant benefit of external radiotherapy on overall or disease-specific survival. In fact, several studies, including the Aalders's and PORTEC randomised trials, have shown non-significant trends towards poorer disease-specific survival among early stage endometrial cancer patients who were treated with external radiotherapy, particularly among patients with low-risk lesions (low grade and superficial myometrial invasion) [9,10,12-15].

It is important to confirm the results of randomised controlled trials in daily practice settings because randomised controlled trials are generally executed in specialised centres and mainly involve experts and highly dedicated physicians. Therefore, we exploited our population-based cancer registry data to evaluate the impact of external radiotherapy and brachytherapy on the survival of patients who underwent surgery for stage I endometrial cancer in the Swiss canton of Geneva.

Materials and Methods

We used data from the Geneva Cancer Registry to identify all female residents of the canton of Geneva who were diagnosed with corpus uteri cancer between 1980 and 1996 (n=731). We excluded patients with the following clinical characteristics: invasive malignancies that occurred within the five years prior to, or six months after the diagnosis of endometrial cancer (n=74); lack of surgical treatment of their endometrial cancer (n=87); and uterine sarcomas (n=41). We limited...
our study to patients with endometrial cancer that was confined to the uterus (regardless of the presence of tumour cells in the peritoneal washing fluid) [16]; 122 patients with more advanced stages were excluded. We excluded the 95 women with stage IA endometrial cancer (i.e., no invasion of the myometrium) because it is generally accepted that these women do not need radiotherapy. Similarly, 20 women with poorly differentiated tumours with greater than 50% myometrial invasion (stage IC grade 3) were also excluded because adjuvant therapy is commonly indicated for these women. We excluded an additional 22 women with missing information on the histology or grade of the tumour or the type of radiotherapy. The remaining 270 patients were included in the study.

The tumours were surgically staged and coded according to the FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) system from 1988. Surgical treatment generally consisted of hysterectomy and oophorosalpingectomy. Lymphadenectomy was not routinely performed.

Geneva University Hospitals have the only radiation therapy centre in this canton, and every patient treated for endometrial cancer underwent radiotherapy there. All patients underwent a fluoroscopic simulation prior to radiotherapy. Simulation films were obtained for the anterior field and one lateral field. During the first week of radiotherapy, the position of the radiation fields was controlled by performing gammaradiographs.

External radiotherapy was delivered using a 4 field technique (box); 26 fractions (range 24-28) were provided with an average dose per fraction of 1.8 Gray (Gy) (range 1.8 - 2.0 Gy) and with an average cumulative dose of 48 Gy (range 45-50 Gy). The energy varied between 6 and 18 Megavolts.

Brachytherapy was performed using either Caesium 137 or Iridium 192; 75% of the patients were treated with Caesium 137. The mean doses were 43.8 for Caesium 137 (in general, prescribed in one fraction) and 19 Gy for Iridium 192, which was prescribed in 3 fractions. Doses were delivered at a 5-mm depth below the mucosal surface on a 3-cm length of the vaginal vault. For the purpose of this study, we categorised the type of radiotherapy as no radiotherapy, brachytherapy, or external radiotherapy with or without brachytherapy.

Histological type and degree of differentiation were coded according to the International Classification of Diseases for Oncology [17]. All pathology reports were reviewed. Stages IB and IC are also described as conditions with superficial and deep invasion, respectively.

Based on previous studies [9,18], we regrouped patients into ‘low-risk’ and ‘high-risk’ tumour profiles according to the degree of myometrial invasion and tumour differentiation. The low-risk group included patients with well or moderately differentiated tumours with less than 50% myometrial invasion (stage IB (superficial invasion), grades 1 and 2). The high-risk group included 108 patients with either poorly differentiated tumours with less than 50% myometrial invasion (stage IB, grade 3) or well or moderately differentiated tumours 50% or more myometrial invasion (stage IC (deep invasion), grades 1 and 2).

Other variables of interest included the following: age at diagnosis (<50, 50-69, ≥70 years), healthcare sector (private clinics vs. public hospitals) and period of diagnosis (1980-87, 1988-96). The data on the survival were derived from the Geneva Cancer Registry and included vital status, date of death or date of departure from the canton (regularly and systematically obtained from the Cantonal Population Office). In addition to passive follow-up (routine examination of death certificates and hospital records), an active follow-up was routinely performed each year using the files from the Cantonal Population Office. The cause of death was systematically recorded, and specially trained medical staff routinely validated the cause of death by consulting the medical files or by sending a questionnaire to the treating physician.

**Statistical analyses**

Comparison of patients and tumour characteristics according to type of radiotherapy was performed using a chi-square test for heterogeneity. Using the actuarial method, we calculated the five-year overall survival rates considering all deaths that occurred in the cohort and the five-year disease-specific survival rates considering only deaths from endometrial cancer. We identified factors that were significantly associated with survival by means of a univariate Cox proportional hazards analysis (unadjusted hazard ratios). To identify significant and independent predictors of survival, we performed a multivariate Cox proportional hazards analysis, adjusting for age and all factors that were significantly linked to mortality in the univariate analysis (adjusted hazard ratios). We performed these analyses for both overall mortality and endometrial cancer-specific mortality. We repeated these analyses excluding patients with papillary and clear cell carcinoma because these histologies are associated with more aggressive tumour behaviour. Disia Statistical analyses were performed with SPSS (version 11.5), and the differences were considered statistically significant if the two-sided p value was <0.05.

**Results**

Of the 270 women included in this study, 87 (32%) did not undergo radiotherapy, 94 (35%) received only brachytherapy, and 89 (33%) were treated with external radiotherapy with or without brachytherapy. Table 1 describes the demographic, tumour and treatment characteristics according to the type of radiotherapy. Women who received external radiotherapy were on average 4 years younger than the non-irradiated women. The proportion of patients treated without radiotherapy increased over the study period; between 1980 and 1987, 23% were not irradiated vs. 40% between 1988 and 1966. The proportion of patients treated with brachytherapy decreased from 43% to 28%, and the proportion of patients treated with external radiotherapy remained relatively stable. Patients treated in private clinics were less often irradiated, whereas patients treated in public hospitals received brachytherapy more frequently. We observed no significant differences in the surgical treatment between non-irradiated and irradiated patients, and the majority (94% on average) of patients were treated with hysterectomy and bilateral oophorosalpingectomy. Only 3 patients (1%) underwent lymphadenectomy.

The patients treated with external radiotherapy had a less favourable tumour profile. Only 26 (29%) of them had low risk disease (i.e., superficial myometrial invasion, grades 1-2) compared to 75 (80%) of the patients treated with brachytherapy and 61 (70%) of the non-irradiated patients (p<0.0001).

The median follow-up was 118 months. Fourteen women (5%) had less than five years of follow-up. Figure 1 presents the five-year overall survival curves according to type of radiotherapy. For non-irradiated patients, patients treated with brachytherapy, and patients treated with external radiotherapy with or without brachytherapy, the five-year overall survival rate was 87% (95%CI: 80-94%), 91% (95%CI: 86-97%), and 84% (95%CI: 76-92%), respectively.

Table 2 shows the overall and endometrial cancer survival rates and the unadjusted and multi-adjusted mortality risks according to patient...
Table 1: Patient, tumour and surgical characteristics according to type of radiotherapy.

<table>
<thead>
<tr>
<th>Radiotherapy</th>
<th>No radiotherapy (n=87)</th>
<th>Brachytherapy (n=94)</th>
<th>Externala (n=89)</th>
<th>Total (n=270)</th>
<th>P-value of chi-square test for heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N %</td>
<td>N %</td>
<td>N %</td>
<td>N %</td>
<td></td>
</tr>
<tr>
<td>Mean age (range)</td>
<td>66.7 (38-91)</td>
<td>64.9 (35-90)</td>
<td>62.9 (33-81)</td>
<td>64.8 (33-91)</td>
<td></td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70+</td>
<td>36 40</td>
<td>30 34</td>
<td>23 26</td>
<td>89 100</td>
<td>.092</td>
</tr>
<tr>
<td>50-69</td>
<td>43 26</td>
<td>60 37</td>
<td>61 37</td>
<td>164 100</td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>8 47</td>
<td>4 24</td>
<td>5 29</td>
<td>17 100</td>
<td></td>
</tr>
<tr>
<td>Period of diagnosis</td>
<td>1980-1987</td>
<td>29 23</td>
<td>54 43</td>
<td>43 34</td>
<td>126 100</td>
</tr>
<tr>
<td>1988-1996</td>
<td>58 40</td>
<td>40 28</td>
<td>46 32</td>
<td>144 100</td>
<td></td>
</tr>
<tr>
<td>Healthcare sector</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private</td>
<td>50 41</td>
<td>34 28</td>
<td>37 31</td>
<td>121 100</td>
<td>.012</td>
</tr>
<tr>
<td>Public</td>
<td>37 25</td>
<td>60 40</td>
<td>52 35</td>
<td>149 100</td>
<td></td>
</tr>
<tr>
<td>Surgical treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hysterectomy with annexectomy</td>
<td>80 32</td>
<td>87 34</td>
<td>86 34</td>
<td>253 100</td>
<td>.535</td>
</tr>
<tr>
<td>Hysterectomy without or unknown annexectomy</td>
<td>7 41</td>
<td>7 41</td>
<td>3 18</td>
<td>17 100</td>
<td></td>
</tr>
<tr>
<td>Tumour risk categorya</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage IB grade 1</td>
<td>52 44</td>
<td>55 47</td>
<td>10 9</td>
<td>117 100</td>
<td>.000</td>
</tr>
<tr>
<td>Stage IB grade 2</td>
<td>9 20</td>
<td>20 44</td>
<td>16 36</td>
<td>45 100</td>
<td></td>
</tr>
<tr>
<td>Stage IB grade 3</td>
<td>6 32</td>
<td>5 26</td>
<td>8 42</td>
<td>19 100</td>
<td></td>
</tr>
<tr>
<td>Stage IC grade 1</td>
<td>14 22</td>
<td>9 14</td>
<td>40 63</td>
<td>63 100</td>
<td></td>
</tr>
<tr>
<td>Stage IC grade 2</td>
<td>6 23</td>
<td>5 19</td>
<td>15 58</td>
<td>26 100</td>
<td></td>
</tr>
<tr>
<td>Risk categorya</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>61 38</td>
<td>75 46</td>
<td>26 16</td>
<td>162 100</td>
<td>.000</td>
</tr>
<tr>
<td>High risk</td>
<td>26 24</td>
<td>19 18</td>
<td>63 58</td>
<td>108 100</td>
<td></td>
</tr>
</tbody>
</table>

*aExternal = external radiotherapy with or without brachytherapy
bStage IB: myometrial invasion < 50%; Stage IC: myometrial invasion >= 50%

Table 3 shows the overall and disease specific survival rates and mortality risks according to type of radiotherapy for all patients combined and for low-risk and high-risk patients separately. For all patients combined, univariate analysis showed that neither brachytherapy nor external radiotherapy significantly modified overall or disease specific mortality risks. However, after adjusting for age, sector of care and tumour profile, we observed that patients treated with external radiotherapy had a 3.2-fold (multi-adjusted HR 3.2, 95% CI: 1.2-8.7, p=0.020) increased overall mortality risk compared to non-irradiated patients. After adjustment for age and tumour profile, the risk of death from endometrial cancer showed a 3.6-fold increase, which was not significant (hazard ratio 3.6, 95% CI: 1.0-13.4, p=0.059).

In the category of patients with low-risk tumours, external radiotherapy significantly increased both the overall mortality risk (multi-adjusted hazard ratio 6.4, 95% CI: 1.3-30.2, p=0.020) and the risk of dying from endometrial cancer (multi-adjusted hazard ratio 9.4, 95% CI: 1.0-86.7, p=0.047).

For high-risk patients, neither external radiotherapy nor brachytherapy modified the overall and endometrial cancer specific mortality risks. Compared to non-irradiated patients, those treated with brachytherapy were at a similar risk of dying from all causes (multi-adjusted hazard ratio 1.0, 95% CI: 0.2-4.3, p=0.973) and from endometrial cancer (multi-adjusted hazard ratio 1.6, 95% CI: 0.3-8.1, p=0.564). Similarly, external radiotherapy did not significantly modify the overall mortality risk (multi-adjusted hazard ratio 1.7, 95% CI: 0.5-6.3, p=0.396) or the risk of dying from endometrial cancer (multi-adjusted hazard ratio 1.9, 95% CI: 0.4-9.1, p=0.453).

When we repeated the analyses excluding the 10 patients with clear and tumour characteristics. The patient and tumour characteristics that were associated with overall mortality in univariate analysis were sector of care and tumour profile (grade/myometrial invasion). After adjustment for age, sector of care, tumour profile and type of radiotherapy, tumour profile was still linked to overall mortality. In particular, patients with poorly differentiated, superficially invasive tumours had a five-fold increased risk of death from all causes (hazard ratio 5.1, 95% CI: 1.3-19.8).

Table 2 also shows that among all patient and tumour characteristics, only tumour profile was linked to death from endometrial cancer in univariate analysis. After adjustment for age and type of radiotherapy, the risk of death from endometrial cancer remained significantly increased for patients with poorly differentiated, superficially invasive tumours (hazard ratio 8.8, 95% CI: 1.9-40.1).
Mortality from endometrial cancer

Overall mortality | Mortality from endometrial cancer
---|---
N | Deaths N | 5-year survival (95% CI) | Unadjusted HR (95% CI) | p-value | Adjusted HR (95% CI)| p-value | Deaths N | 5-year survival (95% CI) | Unadjusted HR (95% CI)| p-value | Adjusted HR (95% CI)| p-value
---|---|---|---|---|---|---|---|---|---|---|---|---
Age
<50 | 17 | 1 | 94% (83-100) | 1<sup>a</sup> | 1<sup>a</sup> | 1 | 94% (83-100) | 1<sup>a</sup> | 1<sup>a</sup>
50-69 | 164 | 7 | 96% (92-99) | 0.7 (0.1-5.4) | 700 | 0.6 (0.1-4.9) | 62.8 | 5 | 97% (94-100) | 0.5 (0.1-4.0) | 491 | 0.5 (0.6-4.2) | 512
70+ | 89 | 25 | 71% (62-81) | 5.0 (0.7-37.0) | 114 | 4.4 (0.6-33.1) | 13 | 84% (76-92) | 2.6 (0.3-19.8) | 359 | 3.9 (0.5-30.5) | 196
Period
1980-1987 | 126 | 15 | 88% (82-94) | 1<sup>a</sup> | 1<sup>a</sup> | 1 | 93% (88-97) | 1<sup>a</sup> | 1<sup>a</sup>
1988-1996 | 144 | 18 | 87% (82-93) | 1.1 (0.5-2.1) | 835 | 0.8 (0.4-1.7) | 580 | 10 | 93% (88-97) | 1.0 (0.4-2.4) | 982 | 0.5 (0.2-1.5) | 217
Sector of care
Private | 121 | 9 | 92% (87-97) | 1<sup>a</sup> | 1<sup>a</sup> | 1 | 95% (92-100) | 1<sup>a</sup> | 1<sup>a</sup>
Public | 149 | 24 | 84% (77-90) | 2.3 (1.1-5.0) | 033 | 2.0 (0.9-5.0) | 150 | 14 | 90% (85-95) | 2.4 (0.9-6.7) | 089 | 3.7 (1.0-14.0) | 054
Risk category
1b Grade 1 | 117 | 10 | 91% (86-96) | 1<sup>a</sup> | 1<sup>a</sup> | 3 | 97% (94-100) | 1<sup>a</sup> | 1<sup>a</sup>
1b Grade 2 | 45 | 7 | 89% (80-98) | 1.4 (0.5-4.1) | 543 | 1.8 (0.6-5.1) | 310 | 4 | 91% (82-100) | 3.7 (0.8-16.6) | 086 | 3.3 (0.7-15.4) | 122
1b Grade 3 | 19 | 4 | 78% (58-98) | 2.8 (0.9-8.8) | 087 | 5.1 (1.3-19.8) | 017 | 4 | 78% (58-98) | 9.1 (2.0-40.7) | 004 | 8.8 (1.9-40.1) | 005
1c Grade 1 | 63 | 8 | 87% (78-96) | 1.6 (0.6-4.0) | 33 | 1.3 (0.5-3.3) | 565 | 3 | 95% (89-100) | 2.0 (0.4-9.8) | 401 | 1.0 (0.8-16.8) | 381
1c Grade 2 | 26 | 6 | 77% (61-93) | 2.8 (1.0-7.7) | 046 | 2.0 (0.7-5.6) | 185 | 5 | 81% (65-96) | 7.7 (1.8-32.1) | 005 | 3.8 (0.8-16.8) | 083

Table 2: Number of deaths, overall and five-year disease-specific survival and all cause mortality and endometrial cancer mortality risks according to patient and tumour characteristics.

Discussion

This study confirms the findings of previous studies and showed that radiotherapy does not improve disease specific or overall survival in patients with early stage endometrial cancer. More importantly, we observed that external radiotherapy, with or without brachytherapy, is associated with an increased overall and endometrial cancer mortality risk among patients with well or moderately differentiated superficially invasive endometrial cancer.

External radiotherapy has clearly shown its importance in reducing loco-regional recurrence [9, 12, 15, 19, 20, 21, 22].

Two recent randomised controlled trials showed that adding external radiotherapy to surgery for stage I endometrial cancer reduced recurrence rates from approximately 12-15% to 3-4% [9, 10]. However, the effect of radiotherapy on overall and disease specific survival is less well understood. Before publication of the results of the two randomised trials, the available literature showed ambiguous results; some studies reported non-significant trends towards poorer survival rates among cell or papillary tumours (n=3 and n=7, respectively), the results were not significantly modified.

Table 3: Number of deaths, overall and five-year disease-specific survival and all cause mortality and endometrial cancer mortality risks according to type of radiotherapy for low risk and high risk patients.

J Cancer Sci Ther 3: 041-046 (2011) - 044
women who were treated with external radiotherapy [16,23], whereas others observed improved survival among irradiated women [3,24].

Aalders et al. [8] treated all stage I patients with brachytherapy and then randomised them to external radiotherapy or no further treatment [8]. They found no five-year overall survival difference between patients treated with only brachytherapy compared to those treated with both brachytherapy and external radiotherapy (89% vs. 91%, respectively).

The PORTEC trial’s eight- and ten-year updates showed that external radiotherapy strongly reduces the risk of loco-regional recurrence among women with stage I disease (superficial invasion grade 2-3 and deep invasion grade 1-2). However, no significant survival differences were found between irradiated and non-irradiated patients. In fact, there was a non-significant reduced risk of death from endometrial cancer among patients who did not receive radiotherapy (hazard Ratio 0.7, 95% CI 0.4-1.2) [15,22,25].

In the randomised trial by the Gynecologic Oncology Group, patients with superficially and deeply invasive endometrial cancer limited to the uterus and patients with endometrial cancer showing microscopic invasion of the cervix were randomised to postoperative external radiotherapy and surgery only. There was no significant survival difference between the two study arms. However, among patients with high-risk lesions, there was a non-significant trend towards better overall and disease specific survival among irradiated patients, whereas among women with low-risk tumours (superficial myometrial invasion, grades 1 and 2), there was a 2.4-fold (non-significant) increased risk of dying from endometrial cancer.

Our population-based data are consistent with the trends observed in the two most recent randomised trials [9,10]. Adjuvant radiotherapy might do more harm than good in a small minority of patients. Recently, the harm and benefit of adjuvant radiotherapy in intermediate risk endometrial cancer has been weighed [26]. They conclude that out of every 1000 women, 4 will die because of radiotherapy sec. We have included that reference in the text. Nevertheless, we are the first to report significantly increased overall and endometrial cancer mortality risk among low-risk patients. However, our study is not randomised, and consequently, there are baseline differences between the patients who received no radiotherapy, brachytherapy or external radiotherapy. Although we adjusted our models for the most important prognostic factors (age, myometrial invasion and grade), we were unable to adjust for other prognostic factors, such as lymphovascular invasion or the diameter of the tumour. Creutzberg et al. [27] showed that in combination with differentiation and myometrial invasion, lymphovascular invasion is not an independent prognostic factor; however, we cannot determine whether not considering that parameter influenced the results [27].

In addition to a lack of survival benefit, the randomised controlled trials also showed a significant increase in complications among irradiated patients and it can be assumed that external radiotherapy affects long-term quality of life as well [9,10].

Additionally, patients who were treated with external radiotherapy and developed a vaginal recurrence have a significantly lower chance of recovering from this relapse than patients who were initially treated with surgery (5% vs. 30%, respectively) [13,14,25,27,28].

As a result, a more effective strategy might be to reserve radiation therapy for patients who develop a relapse.

In conclusion, our population-based data support the opinion of some authors that external radiotherapy should be discouraged in patients with stage I endometrial cancer, except for poorly differentiated, deeply invasive tumours [29-32].

References
20. Piver MS, Hempling RE (1990) A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic


